University of Notre Dame
Browse

File(s) under embargo

1

year(s)

10

month(s)

25

day(s)

until file(s) become available

Rapid Membrane-Based Digestion and Purification For LC-MS Protein Analysis

dataset
posted on 2024-11-18, 16:09 authored by Weikai Cao
Glycosylation plays a critical role in the bioactivity of proteins. For example, glycosylation of the SARS-CoV-2 Spike receptor-binding domain affects viral entry into host cells. Similarly, the glycosylation of erythropoietin and monoclonal antibodies significantly influences their pharmacokinetic and pharmacodynamic properties. The bottom-up approach, which enables the attachment of glycans to peptides, is one of the most straightforward methods for studying protein glycosylation by liquid chromatography-mass spectrometry (LC-MS). In addition to identifying non-glycosylated peptides, it facilitates the analysis of site-specific glycosylation. However, this approach typically requires several hours or even overnight digestion. The digestion process becomes even more prolonged when multiple proteases are needed, which significantly hampers the efficiency of protein glycosylation analysis. The research presented in this dissertation utilized protease-immobilized membranes to enable rapid protein digestion. This method achieves comparable glycan identification and semi-quantitative assessments to conventional overnight in-solution digestion. Further studies explored the use of tandem membranes, consisting of trypsin-immobilized membranes and C18-derivatized membranes, to streamline protein digestion and peptide purification. During centrifugation, proteins are initially digested in the first layer (trypsin-immobilized membranes), and the resulting peptides are subsequently enriched in the second layer (C18-derivatized membranes). Most salts and contaminants pass through the membranes and are effectively removed from the protein digests. This technique has been successfully applied to the sequence and glycosylation analysis of commercial monoclonal antibodies (Kanjinti, Bevacizumab, and Rituximab), as well as to the analysis of host cell proteins and in-house expressed antibodies. This prototype could prove valuable for real-time monitoring of product glycosylation, ensuring the consistency and efficacy of therapeutic agents.

History

Date Created

2024-11-04

Date Modified

2024-11-18

Defense Date

2024-09-03

CIP Code

  • 14.0701

Research Director(s)

Merlin Bruening

Committee Members

Paul Bohn Matthew Champion Basar Bilgicer

Degree

  • Doctor of Philosophy

Degree Level

  • Doctoral Dissertation

Language

  • English

Library Record

006638312

OCLC Number

1470964691

Publisher

University of Notre Dame

Additional Groups

  • Chemical and Biomolecular Engineering

Program Name

  • Chemical and Biomolecular Engineering

Usage metrics

    Dissertations

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC